Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
everything's postive about CBAI-more and more folks getting in or will be investing in the future- i believe the time is now to get in-this is the ground floor-next week will be new higher highs and folks will hate that they didn't get in @ theses levels-with the Time Mag cover story of stem cells-02/09/09(super mainstream) -i believe it will cause obama to speak and act sooner on the stem cell subject bring so much attention to us -ALL ABOARD
ps don't u understand everybody will be talking about stem cells next week -msnbc-cnn-fox news-even cramer
CBAI worth taking a look @ CBAI
Websites:
http://www.cordblood-america.com
http://www.cordpartners.com
http://www.cord-blood-video.com
http://www.curesource.net
http://www.corcell.com
all news
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=CBAI
http://www.time.com/time/covers/0,16641,20090209,00.html
http://www.washingtontimes.com/news/2009/feb/06/obama-guarantees-aiding-stem-cell/
dang look at the boardmarks we were just at 150 -wow i feel we're at the right place at the right time on this one go go go CBAI looking for a major run on monday-friday next week
BUY
CONFIRMED
very bullish starting on monday 9=time mag = $
BUY
CONFIRMED
http://www.ddmachine.com/
also in that same pr obama stated he's going to fix it so it could never be reverse again by future presidents stem cells for life ---c ya on monday weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
February 1, 2009
US move to lift stem cell ban sparks Scottish brain drain fear
Barack Obama’s pledge to allow government cash to once again be spent on stem cell research could lead to scientists — and money — leaving for America
Barack Obama’s pledge to overturn a ban on US government funding for stem cell research could have disastrous consequences for Scottish universities, senior scientists warn.
John Ansell, the director of project development at the UK Stem Cell Foundation, said that the policy could lead to a brain drain of scientists and declining funding for Scottish research.
Following the ban imposed in 2001 by George Bush, who opposed the use of embryos for research, Scottish universities benefited from an influx of funding which helped make Scotland a world leader in the field.
However, it is widely expected that Obama, a strong supporter of stem cell research, will soon overturn Bush’s restrictions. Last month America’s Food and Drug Administration approved the first human trial using embryonic stem cells for paraplegics who can use their arms but cannot walk.
Related Links
Beware a Scottish stem cell brain drain
The change in policy would have serious implications for the Scottish stem cell research industry. It had been estimated that the research could by worth at least £50m a year to the Scottish economy by 2015.
Scientists fear experts will be drawn to America by higher salaries and state-of-the-art facilities receiving federal funding.
They have also criticised the UK government for refusing to provide funding to conduct large-scale medical trials, a vital step towards turning laboratory research into a potentially lucrative clinical application.
“The way the US state budgets have been regulated, there’s been a window of opportunity to be in the lead, but because of funding difficulties, that window hasn’t been exploited to the best effect,” said Ansell.
“The window’s getting smaller. And there aren’t that many stem cell biologists in the world, so if America opens up with funding, then retaining personnel becomes a problem.”
Stem cells are able to develop into almost any other cell type. Scientists hope to harness their properties to generate tissue to replace that damaged by trauma, or compromised by disease.
Two small-scale medical trials are due to take place in Scotland this year; one in Glasgow to study the use of adult stem cells to treat stroke patients, the other in Edinburgh for the treatment of corneal blindness.
“If the trials turn out to be successful, lots of money will start rolling in,” added Ansell. “We still have an advantage, but it’s going to disappear, especially if America puts more money from the state into this.” The next trial in the pipeline in Scotland is the use of stem cells to repair damaged cartilage. Led by Dr Brendon Noble, of Edinburgh University’s centre for regenerative medicine, the trial is a collaboration with Geron, an American biotech firm.
Noble said he shared Ansell’s concerns about the likely impact of a change in US policy. “What we have done in Scotland is build up a nice pool of expertise and it would be a crime if we lost people,” he said. “We need to keep things going here.”
http://www.timesonline.co.uk/tol/news/uk/scotland/article5627308.ece
yeah selling now is crazy---with the time mag cover story monday this is going to fly ---- going to make obama bring attention to lifting the ban much faster ---next week after the time cover story --obama should speak on this ---BUY ON DIPS
ALERT: BULLISH REVERSAL PATTERN
AmericanBulls.com says
Today a White Candlestick was formed. This represents normal buying pressure.
For more about this candlestick click here.
The last two candlesticks formed a Bullish Harami Pattern . This is a bullish reversal pattern that marks a potential change in trend.
http://www.ddmachine.com/
good day of tradeing today go go CBAI
more bounce to the ounce -muchful bounce mama
STEM CELLS NEWS
http://seattlepi.nwsource.com/swift/398637_mary05.html?source=mypi
Putting a face on the stem cell argument
By MARY SWIFT
P-I COLUMNIST
SOMETIME SOON, perhaps even this week, President Barack Obama is expected to lift federal regulations on the use of embryonic stem cells in medical research.
With recently awarded FDA approval, a California biotech firm sits poised to begin the world's first human trial that will involve injecting embryonic stem cells into the spinal cords of people who are paralyzed.
The subject spurs heated debate. Advocates believe it will throw open the door to medicine's future. Opponents say it destroys life.
At the heart of the debate, but on the sidelines of the fight, Jacob Coffron, soon to turn 18, sits in a wheelchair and breathes with the help of a ventilator.
His is the human face of the argument for embryonic stem cell research.
At 15, he fell while climbing over a fence outside his mother's Des Moines apartment.
He hasn't breathed on his own since. A month at Harborview was followed by four months at Seattle Children's, then he came home.
His mom, Amy Garnett, cares for him during the day. An aide comes in at night. Twice a week, he goes to Redmond's Pushing Boundaries, an organization that offers exercise therapy for victims of spinal cord injury.
Time has transformed him from a young teen into a near-man. He is husky and has the beginnings of a beard.
Dressed in dark sweat pants, and a black and gray T-shirt decorated with the image of a wizard and a dragon, he sat in a wheelchair in his bedroom one recent morning with a black watch cap pulled down close to his eyes. For a time he sat covered by a comforter he has to ask to have removed.
"I get so cold sometimes that I can't get warm," said Coffron, who by nature is quiet, understated -- and given to a dry sense of humor that surfaces in one-liners.
He wears metal studs in his lips and metal wires in his ears.
A poster from "Lord of the Rings" and one of the Three Stooges decorate the walls. A collection of miniature dragons sits on one shelf. Across the room, wire baskets holding an assortment of medical supplies hang on the wall next to his bed where his 12-year-old brother Cole sprawls companionably.
A silver-colored basketball -- a gift from a friend -- serves as a bittersweet reminder of a former passion."What I miss most is basketball, just playing for fun," Coffron said.
He's planning on a tattoo when he turns 18 next month, dreams about someday living in his own apartment and smiles wryly when he's asked about his "good" days.
"A good day is when they're not yelling," he said, mounting a lighthearted jab at his mother and grandmother, Jane Coffron of Kent. They laughed.
He drew more laughter when asked what he liked to eat.
"A lot," he deadpanned, flashing a fleeting smile.
After his accident, Coffron went back to Mount Rainier High briefly but eventually dropped out. At his mother's urging, he's now talking about getting a tutor and working on his GED.
His father, Terry Hornbeck, lives nearby and has a knack for treating his son like a buddy, a gift not lost on his son, who calls him "more like a friend than a dad."
Struggling to understand why an act as innocent as climbing over a fence ended so badly, he said, "I still haven't found the answer."
Behind him, Jane Coffron dabbed at her eyes. That ques-
tion -- and its unfathomable an-
swer -- is still emotional for her.
But she is steadfast in her belief that embryonic stem cell research is the key to her grandson's future.
"With it, there's hope," she said. "This is the first time that someone with his type of injury can look forward and have real hope."
As discussion swirled around him, he listened without speaking, his expression set.
Coffron's not about to kiss off hope. But right now he's busy coping with the present -- not politics.
"I don't know," he said softly when he spoke again. "I just take one day at a time."
http://www.lifesitenews.com/ldn/2008/sep/08091905.html
SOME GOOD READING obama is a man of his word
McCain, Obama Defend Embryonic Stem Cell Research
McCain's support more qualified, expressed concern about violation of "ethical principles"
By Kathleen Gilbert
WASHINGTON, D.C., September 19, 2008 (LifeSiteNews.com) - In a Monday interview with Science Debate 2008, presidential nominees John McCain and Barack Obama reiterated their individual positions on the embryonic stem cell (ESC) research debate, with both candidates again stating that they support ESC research.
In the interview Barack Obama criticized Bush administration funding restrictions for "handcuffing" scientific progress, while Sen. McCain said that, while ESC is acceptable, moral and ethical values should not be violated by creating embryos specifically for stem cell harvesting.
ScienceDebate2008.com asked both candidates, "Stem cell research advocates say it may successfully lead to treatments for many chronic diseases and injuries, saving lives, but opponents argue that using embryos as a source for stem cells destroys human life. What is your position on government regulation and funding of stem cell research?"
Sen. Barack Obama responded by listing possible uses for embryonic stem cells in future medicine, and for these reasons said he strongly supports expanding research on embryonic stem cells. Obama also expressed concern that without federal funding for ESC research, America will fall behind on the international stage.
"I believe that the restrictions that President Bush has placed on funding of human embryonic stem cell research have handcuffed our scientists and hindered our ability to compete with other nations," he said. As president, Obama guaranteed he would ensure all research on stem cells is conducted "ethically and with rigorous oversight."
Addressing the objection that ESC research requires harvesting cells from and destroying innocent human life, Sen. Obama explained that "hundreds of thousands of embryos stored in the U.S. in in-vitro fertilization clinics will not be used for reproductive purposes, and will eventually be destroyed. I believe that it is ethical to use these extra embryos for research that could save lives when they are freely donated for that express purpose."
Obama also said he disagreed with the mounting evidence that indicates stem cells from alternate sources continue to show more promise than embryonic stem cells. He argued that embryonic stem cells still have more "versatility" and remain the "gold standard."
Senator McCain's response was more qualified and seemingly reflected some consideration of meetings he has had recently with leading opponents of embryonic stem cell research. At the recent Catholic Leadership Conference in Charlotte, North Carolina, Dr. Jack Willke, former head of National Right to Life, revealed he has had two very recent meetings with McCain during which he presented much information on the subject to the Republican presidential candidate.
In his shorter response, McCain expressed his belief that embryonic stem cell research should receive federal funding. At the same time, he said, efforts should be made to ensure that such research does not violate "ethical principles."
"While I support federal funding for embryonic stem cell research, I believe clear lines should be drawn that reflect a refusal to sacrifice moral values and ethical principles for the sake of scientific progress," said McCain.
"Moreover, I believe that recent scientific breakthroughs raise the hope that one day this debate will be rendered academic," he continued, citing other stem cell research that does not require the destruction of embryos.
"I oppose the intentional creation of human embryos for research purposes and I voted to ban the practice of 'fetal farming,' making it a federal crime for researchers to use cells or fetal tissue from an embryo created for research purposes," said McCain.
ScienceDebate2008.com is a non-partisan group of scientists, engineers, and other professionals campaigning to bring scientific issues to American political dialogue and debate.
IT WILL HAPPEN----- In Inaugural Address, Obama Vows To 'Restore Science' To 'Rightful Place'
Obama Executive Orders Will fund Abortion, Embryonic Stem Cell Research (executive order is all it takes)
http://www.nowpublic.com/world/obama-executive-orders-will-fund-abortion-embryonic-stem-cell-research
http://www.lifenews.com/nat4559.html
Obama Executive Orders Will fund Abortion, Embryonic Stem Cell Research (executive order is all it takes)
http://www.philly.com/inquirer/health_science/daily/20090203_Obama_keeping_stem-cell_advocates_waiting.html
Obama keeping stem-cell advocates waiting
By Marie McCullough
Inquirer Staff Writer
Within days of taking office, President Obama was expected to sign an executive order to remove Bush-era federal funding limits on embryonic-stem-cell research.
Now that days are turning into weeks, proponents of the research are looking for explanations while insisting that Obama's support has not wavered.
Rep. Mike Castle (R., Del.), a congressional champion of the research, said that last week, he explicitly asked White House officials about it.
"I believe there will be an executive order lifting the funding ban," Castle said. "My speculation is that it will happen in a few weeks. . . . They've had a lot of things to deal with. I see no bump in the road."
On the campaign trail, Obama pledged to revoke the policy that President George W. Bush imposed in August 2001. Bush said federal dollars could be used only for research on several dozen stem-cell colonies, or "lines," that already existed. About 20 "presidential lines" are still viable, but researchers say they need access to newer lines to make progress.
This quasi-ban on funding was an effort to appease both sides in the debate over research using embryonic stem cells. Abortion foes say it is immoral because embryos are destroyed in the process, while polls indicate that a majority of Americans see it as a promising path toward therapies for such intractable conditions as Alzheimer's disease, Parkinson's disease and paralysis.
Not until four days before the inauguration, during a CNN interview, did Obama say he would "prefer" that Congress pass legislation removing Bush's restrictions, "because those are the people's representatives."
That comment prompted some patients' groups to gripe that Obama was backpedaling on his campaign promise.
Better by law?
But leading scientists also believe that research policy is better set by a comprehensive law than by a revocable directive.
"I would agree with that," said John Gearhart, a stem-cell-research pioneer who was wooed last year from Johns Hopkins University to the University of Pennsylvania. "As researchers, we need a stable base."
"He's not backpedaling," said Wise Young, an internationally known neuroscientist at Rutgers University. "We need a law so we don't have this political football. If Obama simply rescinds the Bush order, it lets Congress off the hook" in dealing with an ethically charged issue.
Not so, said Castle. He said an executive order and legislation should go hand in hand. Even if Obama issues an order, Castle and Rep. Diana DeGette (D., Colo.) intend to reintroduce the Stem Cell Research Enhancement Act, which Congress twice passed and Bush twice vetoed.
Among other things, the bill would allow federal funding of stem-cell research involving spare embryos donated by couples undergoing infertility treatment - embryos that would otherwise be discarded.
"Most members of Congress are supportive and would be happy to vote on the measure," Castle said.
'Pluripotent'
Embryos contain "pluripotent" stem cells - meaning the cells have the power to produce copies indefinitely and morph into the more specialized "adult" stem cells, which yield blood, muscle, nerves and all other tissues.
Another reason Obama may prefer congressional action, observers say, is that Congress perennially renews the 14-year-old Dickey-Wicker Amendment, banning the use of federal money for research that creates or destroys human embryos. The Republican-controlled Congress first passed it as a rider to the budget of the National Institutes of Health, the primary government underwriter of biomedical research.
"It will take courage and farsightedness by congressional stem-cell proponents to do away with this pernicious restriction on potentially lifesaving research," Bernard Siegel, executive director of the Genetics Policy Institute, wrote last month. The Wellington, Fla., institute promotes stem-cell research.
During the last eight years, the NIH, with a $28 billion annual budget, has awarded a relatively minuscule $300 million for research on the Bush-approved embryonic stem-cell lines.
The economic-stimulus package passed last week by the House proposes $3 billion more for NIH.
While stem-cell scientists would welcome a windfall, they would settle for new NIH guidelines that legitimize, rather than stigmatize, their work.
'Open mind'
"All we're asking is for more access to federal money and for our applications to be received with an open mind," Gearhart said.
Currently, labs such as his are subject to rules that stifle collaboration and efficiency. For example, researchers using presidential stem-cell lines must obtain private money to buy and study newer, better cell lines. Equipment bought with federal money cannot be used for experiments with unapproved cell lines.
Lorraine Iacovitti, a Thomas Jefferson University neuroscientist who is testing many types of stem cells to develop therapies for Parkinson's disease, lamented that she spends so much time applying for private grants to replace diminishing NIH support, "we don't have enough time to write scientific papers."
Biotech executives say the ethical debate over embryo destruction, combined with public confusion, has discouraged investment even in noncontroversial adult-stem-cell applications.
"Big biotech companies have steered clear of all stem-cell research because of the political exposure," said Gerri Henwood, chief executive officer of Neuronyx, a Malvern firm that is developing wound therapies from blood stem cells.
If federal funding barriers are removed, companies such as Neuronyx will indirectly benefit "just by opening up the thought that stem cells are not bad, not automatically problematic," she said.
In the last year, critics of embryonic-stem-cell research have pointed to breakthroughs to argue that the promise of regenerative medicine can be achieved without destroying embryos.
It is now possible to genetically induce ordinary cells, such as skin cells, to exhibit the pluripotent characteristics of embryonic stem cells.
Scientists counter that now more than ever, they need to study the cells from which human life stems.
"Embryonic stem cells are still the gold standard," Iacovitti said. "I feel very hopeful about [induced pluripotent] cells. But we have to keep comparing them to embryonic stem cells."
weeeeeeeeeeeeeeeeeeeeee look at all the cheap shares i get to buy b4 time coverage and obama speaks out about stem cell that is happening this week weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
http://www.otcpicks.com/Stocks-To-Watch/
More Stem Cell Agenda News Expected From the Obama Administration This Week
CORD BLOOD AMERICA INCORPORATED (OTCBB: CBAI)
"Up 18.54% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/CBAI.php
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
CBAI News:
January 27 - With the Embryonic Stem Cell Trial Cleared by the FDA as a Key Indicator, Cord Blood America Announces Expansion Plans for Its Stem Cell Storage Program
More Stem Cell Agenda News Expected From the Obama Administration This Week
Cord Blood America, Inc. (OTCBB: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said that it intends a rapid expansion of its health insurance partnership program to new geographies in 2009. This announcement from Cord Blood America comes on the heels of last week's announcement that the Food and Drug Administration and the U.S. government will allow the world's first test in people of a therapy derived from human embryonic stem cells. For more information, see the social media news room at www.intelligendo.com.
Founder and CEO Matthew Schissler, in reviewing the domestic stem cell industry, predicts that 2009 will be an excellent, milestone year for stem cell storage companies, including CBAI. "Now is the right time. We have focused our business on three primary locations for several years, developing deep relationships with health insurance providers to become their recommended source for storage of umbilical cord blood stem cells."
Mr. Schissler says Cord Blood America's stem cell storage subsidiary, CorCell, will attempt to enter into contracts with two or three more geographic health insurance providers, which would double the company's current health insurance provider base.
"With a national health insurance plan and stem cell agenda as two of the primary topics from the new administration, we see a marriage of the insurance companies possibly paying for stem cell storage on the horizon, even if it is on a limited basis for high risk families. By developing the insurance sales channel, we feel we are positioning ourselves for long term success in becoming a globally dominant stem cell storage company."
Mr. Schissler went on to say that the growth will have limited cost because all infrastructure needed has been put into place over the course of many years.
CBAI has a history of being able to finance its growth, with the most recent funding of $4 million transacting in July of 2008. "With a very low cash burn, we feel we're well financed for the next few years," Schissler commented. "We'll use this time to get cash flow positive and reduce debt while growing both organically and through accretive acquisitions."
The company also is reporting tremendous success in engaging its clients, prospective clients, shareholders and prospective investors via social media with the help and intuition of NetGenPR (www.netgenpr.com). Cord Blood America is currently on Twitter, Facebook and Intelligendo, and soon to be available on FriendFeed. Cord Blood America's address on Twitter is www.twitter.com/cbai. "The conversation has begun. Groups from all over are discussing the impact of stem cells on every day life. We're glad we can lead and moderate this information, while trying to be a stem cell company of the people."
As previously reported, from 2003 to 2007, CBAI focused on growth. In 2008, the Company changed its tactics attempting to de-lever the company while becoming purely a stem cell storage company, and in the process de-emphasizing its non-core family advertising business.
As such, Cord Blood America has reported through first nine months:
* Gross profits for the first nine months have increased to $1.8 million, a 54 percent margin, compared to a 42 percent margin in 2007.
* SGA is down nearly $900,000, a 23 percent savings.
* Loss from operations is down nearly 20 percent.
* Loss per share is down 60 percent, from 0.05 to 0.02.
"We believe 2009 to be a turning point year for CBAI. We're excited to get going," Mr. Schissler concluded.
http://www.economist.com/science/displaystory.cfm?story_id=13014104
American attitudes to stem-cell therapies are changing fast
FOR the past eight years, America’s government has declined to fund new research into one of the world’s most promising medical technologies: the use of human embryonic stem cells to repair or replace damaged tissue in the diseased and injured. Embryonic stem cells are special for two reasons, one scientific and one ethical. The scientific reason is that they are able to turn into any of the body’s myriad cell types, which is why they might be used in this way. The ethical reason is that, at the moment, harvesting them usually involves killing human embryos. The embryos in question have no future anyway (they are usually “spares” from in vitro fertilisation procedures). But it was this destruction of potential human life that disturbed George Bush and his supporters.
Barack Obama has promised to reverse the ban. When that happens, American academics will no longer have to watch enviously from the sidelines as their colleagues in Australia, Britain, China, the Czech Republic, Israel, Singapore and South Korea push ahead. But though the legislative wheels have yet to start turning, the mood has already shifted.
One sign of this shift came on January 23rd when the country’s Food and Drug Administration (FDA) granted permission for the first clinical trial of a therapy based on human embryonic stem cells to Geron, a firm based in Menlo Park, California. Geron was able to ask for permission, and the FDA was able to grant it, because the ban does not apply to privately financed research. America, it seems, is back in the stem-cell business.
Off we go
Geron’s trial is of a treatment for paralysis caused by damage to the spinal cord. Between eight and ten patients with severe spinal-cord injuries will be recruited to test this treatment for safety. At the same time both the researchers and the patients will be looking for signs of improvement in the condition. If the trial is successful, larger ones will follow.
The trick that Geron’s researchers have learned is how to turn embryonic stem cells into cells called oligodendrocytes. These, in turn, generate a structure called the myelin sheath, which insulates nerves against leakage of the electrical signals that carry their messages around. Geron plans to inject its oligodendrocytes into the damaged spines of patients between one and two weeks after their injury.
Tests in rats, using human cells, have shown that oligodendrocytes injected this way can indeed help repair myelin sheaths and restore the ability of nerve cells to carry signals. The hope is that the same will happen in people. The nerve cells themselves will not be replaced, so even in principle such treatment could not help everyone with a spinal injury. Many observers do, however, see this research as a step along the road to reconnecting the brains and limbs of those with severed spinal cords, by growing new nerve cells to bridge the gap.
All new medical procedures need to be tested for safety, of course. With stem cells, the main risk is not the sort of chemical toxicity associated with a drug; rather it is of an unusual type of tumour called a teratoma. Teratomas are more or less normal bodily structures—eyes or teeth, for example—that are growing in the wrong place. They are a special risk with stem cells precisely because such cells can turn into any other sort. If the wrong genetic switch is flicked, the wrong sort of tissue results.
Another risk, though, is immune rejection. Introducing stem cells into a body is a bit like transplanting an organ: the recipient’s immune system might throw a wobbly and try to destroy the intruder. Geron’s patients will therefore have to spend two months taking anti-rejection drugs. Other people, though, think they may be able to get round this difficulty. The International Stem Cell Corporation (ISCo), in Oceanside, California, for one, reckons it can do so and, at the same time, deal with the ethical issue of embryo destruction.
ISCo has found a way of producing embryonic-like stem cells from unfertilised eggs. The egg is chemically stimulated to create a group of cells that form a non-viable (and unfertilised) “embryo”. This, explains Kenneth Aldrich, the firm’s boss, is something that could not be implanted into a woman’s womb and produce a child. Nonetheless, the cells it contains have the same characteristics as stem cells.
Besides any ethical advantages this procedure may have, it could also have medical ones. Because lines of stem cells created in this way have only one parent, they are immunologically simpler than normal embryonic cells—in other words they have a smaller variety of the proteins that trigger rejection. That lack of variety, says Dr Aldrich, means it might be feasible to create a bank of stem-cell lines that could be matched to every immune type in the human population, rather as a blood bank carries blood of all the different groups (A, B, O and so on). Replacement stem cells might then be ordered off the shelf.
Nor are spinal-cord injuries the only condition lined up for treatment. Both ISCo and Advanced Cell Technology, of Los Angeles, are trying to create stem cells that could stop—and possibly reverse—a process called macular degeneration, which leads to blindness. ISCo says it hopes to start human trials later this year. Using embryonic stem cells in this way is regarded as a particularly promising route because a similar form of treatment that employs stem cells recovered from still-born children is already known to work.
Try, try, try again
The true potential of this approach is unknowable. It might yet prove too difficult to use as widely as its supporters hope. Stem-cell therapy has been suggested as a way of dealing with arthritis, angina and Parkinson’s disease, as well as spinal-cord injury and blindness—a range of conditions that makes it look like a panacea. That risks disappointment and overreaction if things go wrong. But the only way to find out is to try.
Michael West, the founder of Geron and now head of BioTime, another biotechnology company, says the existing legislation has affected privately financed research as well as the public sort. Investors have been frightened off by the political debate. Once it is gone, the full brunt of America’s innovative know-how, academic and private, could transform the subject, as other countries may soon find out.
cord blood r less Controversial---that is what make this play so good
Weeeeeeeeeeeeeeeeeeeeee! my thoughts as well--next week should be fun ----time to reKABOOOOOOOMM$$$$$$$$$$$$$$$$$$$$$
if u want to get in then get in i think this stock is going to fool alot of people that think it'll be a repeat of what happen on friday---i dont think so----too much is happening right now and next week is going to be a hot week for this one---DONT' SLEEP
so dosn't matter --all about buying pressure --stocks trade in the float anyway --this is headed north--
301,982,188 shares of our common stock are issued and outstanding as of the date of this prospectus.
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6358419
Jan 29, 2009 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: Cord Blood America Inc. (OTCBB: CBAI), Surfect Holdings Inc. (OTCBB: SUFH), Mach One Corporation (OTC: MNCN), Inca Pacific Resources, Inc. (OTC: IPRFF), Canary Resources Inc. (OTC: CYRR), East Japan Railway Co Unsponsored ADR (OTC: EJPRY). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=CBAI
MAN THIS MOSTER IS GOING TO CATCH FIRE NEXT WEEK
need to be buying this is a hot topic for prez obama who is likeiy to be speaking on this next week along with the stimilus bill going to senate
don't worry their r buyers and sellers in this game but don't worry its setting up to head back north now
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=CBAI
BUYINS.NET: CBAI, SUFH, MNCN, IPRFF, CYRR, EJPRY Have Been Removed From Naked Short List Today
Jan 29, 2009 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: Cord Blood America Inc. (OTCBB: CBAI), Surfect Holdings Inc. (OTCBB: SUFH), Mach One Corporation (OTC: MNCN), Inca Pacific Resources, Inc. (OTC: IPRFF), Canary Resources Inc. (OTC: CYRR), East Japan Railway Co Unsponsored ADR (OTC: EJPRY). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
they will be a fool to sell this is right up obama's alley--- less or not as controversial as the other stem cell companies ---dont' matter let em sell iam buying 10cents soon
YEA OUT OF CONTROL
hurry hurry hurry catch the TRAIN
tons of insider trades by this guy Gannon Daniel big news comming as well
Jan 6, 2009 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 513,000
Jan 2, 2009 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 465,274
Dec 31, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 686,802
Dec 30, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 153,350
Dec 29, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 21,475
Dec 26, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 1,328,000
Dec 23, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 1,169,700
Dec 22, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0003 to 0.0004 2,870,077
Dec 19, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004 650,000
Dec 18, 2008 GANNON DANIEL
Beneficial Owner (10%) direct Buy 0.0004
holding up nicely gonna bounce soon
gose up just to go down --tug of war between bulls and bears
its all good
why r they selling or is it dilluteing
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6358419
ABOUT THIS OFFERING
Securities Being Offered
Up to 47,562,096 shares of common stock in Cord Blood America, Inc.
Initial Offering Price
The selling shareholders will sell our shares at prices established on the Over-the-Counter Bulletin Board during the term of this offering, at prices different than prevailing market prices or at privately negotiated prices.
Terms of the Offering
The selling shareholders will determine the terms relative to the sale of the common stock offered in this Prospectus.
Termination of the Offering
The offering will conclude when all of the 47,562,096 shares of common stock have been sold or at a time when the Company, in its sole discretion, decides to terminate the registration of the shares. The Company may decide to terminate the registration if it is no longer necessary due to the operation of the resale provisions of Rule 144 promulgated under the Securities Act of 1933. We may also terminate the offering for no given reason whatsoever.
Tangiers, as an underwriter, cannot avail itself of the provisions of Rule 144 in order to resell the shares of common stock issued to it under the Securities Purchase Agreement.
Risk Factors
The securities offered hereby involve a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See “Risk Factors.”
Common Stock Issued Before Offering
301,982,188 shares of our common stock are issued and outstanding as of the date of this prospectus.
Common Stock Issued After Offering (1)
349,544,284 shares of common stock.
Use of Proceeds
We will not receive any proceeds from the sale of the common stock by the selling shareholders.
(1)
Assumes the issuance to Tangiers of all shares being registered under the Securities Purchase Agreement.
no such news do ya own DD
PRNewswire
Cord Blood America Positioning for Excellent 2009 for Stem Cell Industry
11.17.08, 07:08 AM EST
SANTA MONICA, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that its founder and CEO, Matthew Schissler, in reviewing the year's financial performance, predicted that 2009 will be an excellent, milestone year for stem cell companies, including CBAI.
"The announcement that the incoming Obama Administration will lift the current Administration's ban on Federal funding for research on embryonic stem cells line is the breakthrough the industry and its investors have been waiting for," Mr. Schissler said. "We are very careful to explain that we don't deal with embryonic cells. Cord Blood America collects only umbilical cord blood stem cells at birth. But if researchers can make continued progress and additional discoveries in the use of stem cells to fight diabetes, cancer or heart disease, the number of people wanting to bank their baby's stem cells will increase dramatically."
Yahoo! BuzzMr. Schissler said Cord Blood America focused in 2008 on the future and on becoming purely a stem cell company. "Our de-emphasis on an un-related business to stem cells reduced revenues, from $5.7 million to $3.3 million for the first nine months, however it means we've streamlined our operations to focus on more profitable sectors."
Because of steps taken in 2008, Cord Blood America is reporting: -- Gross profits for the first nine months have increased to $1.8 million, a 54 percent margin, compared to a 42 percent margin in 2007. -- SGA is down nearly $900,000, a 23 percent savings. -- Loss from operations is down nearly 20 percent. -- Loss per share is down 60 percent, from 0.05 to 0.02.
"It is important for our shareholders to understand that we are positioning Cord Blood America to be a key part of what we believe will be an excellent future for the stem cell industry. We know now how many lives are being saved through the use of umbilical cord blood stem cells in the treatment of leukemias and other blood diseases. We are confident many, many more will be saved in the future," Cord Blood America's founder said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com
http://www.forbes.com/prnewswire/feeds/prnewswire/2008/11/17/prnewswire200811170700PR_NEWS_USPR_____LAM063A.html
is it monday yet have we shut the haters up yet - man i am going to make money next week go go go go CBAI
this stock has a long way up to go ----stem cell is the biggest talk right now --especially in califonia obama is going to lift the ban on research real soon because he likes the idea---- look around at the other stem cells buys everybody's flying high just be glad were able to get in on these's levels before this thing takes off-----and oh by the way CBAI----is located in califonia --i look for huge news next week
0.0012 on ask get ready
(bring it on) and ALL HATERS- DON'T HATE PARTICIPATE - GO MODC -MOON BOUND
a bullish reversal -don t count this one out - not done yet